Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
IDX184 in combination with pegylated interferon-α2a and ribavirin for 2 weeks in treatment-naive patients with chronic hepatitis C.
Lalezari J, Box T, O'Riordan W, Mehra P, Nguyen T, Poordad F, Dejesus E, Kwo P, Godofsky E, Lawrence S, Dubuc-Patrick G, Chen J, McCarville J, Pietropaolo K, Zhou XJ, Sullivan-Bólyai J, Mayers D. Lalezari J, et al. Among authors: sullivan bolyai j. Antivir Ther. 2013;18(6):755-64. doi: 10.3851/IMP2552. Epub 2013 Feb 25. Antivir Ther. 2013. PMID: 23439365 Clinical Trial.
Short-term monotherapy with IDX184, a liver-targeted nucleotide polymerase inhibitor, in patients with chronic hepatitis C virus infection.
Lalezari J, Asmuth D, Casiró A, Vargas H, Lawrence S, Dubuc-Patrick G, Chen J, McCarville J, Pietropaolo K, Zhou XJ, Sullivan-Bólyai J, Mayers D. Lalezari J, et al. Among authors: sullivan bolyai j. Antimicrob Agents Chemother. 2012 Dec;56(12):6372-8. doi: 10.1128/AAC.01521-12. Epub 2012 Oct 15. Antimicrob Agents Chemother. 2012. PMID: 23070151 Free PMC article. Clinical Trial.
Rapid decline of viral RNA in chronic hepatitis C patients treated once daily with IDX320: a novel macrocyclic HCV protease inhibitor.
de Bruijne J, van Vliet A, Weegink CJ, Mazur W, Wiercinska-Drapało A, Simon K, Cholewińska-Szymańska G, Kapocsi J, Várkonyi I, Zhou XJ, Temam MF, Molles J, Chen J, Pietropaolo K, McCarville JF, Sullivan-Bólyai JZ, Mayers D, Reesink H. de Bruijne J, et al. Among authors: sullivan bolyai jz. Antivir Ther. 2012;17(4):633-42. doi: 10.3851/IMP2078. Epub 2012 Mar 16. Antivir Ther. 2012. PMID: 22427481 Clinical Trial.
A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4.
Vince B, Hill JM, Lawitz EJ, O'Riordan W, Webster LR, Gruener DM, Mofsen RS, Murillo A, Donovan E, Chen J, McCarville JF, Sullivan-Bólyai JZ, Mayers D, Zhou XJ. Vince B, et al. Among authors: sullivan bolyai jz. J Hepatol. 2014 May;60(5):920-7. doi: 10.1016/j.jhep.2014.01.003. Epub 2014 Jan 14. J Hepatol. 2014. PMID: 24434503 Free article. Clinical Trial.
Single-dose escalation and multiple-dose safety, tolerability, and pharmacokinetics of IDX899, a candidate human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor, in healthy subjects.
Zhou XJ, Pietropaolo K, Damphousse D, Belanger B, Chen J, Sullivan-Bólyai J, Mayers D. Zhou XJ, et al. Antimicrob Agents Chemother. 2009 May;53(5):1739-46. doi: 10.1128/AAC.01479-08. Epub 2009 Feb 17. Antimicrob Agents Chemother. 2009. PMID: 19223643 Free PMC article. Clinical Trial.
First-in-human study of the pharmacokinetics and antiviral activity of IDX375, a novel nonnucleoside hepatitis C virus polymerase inhibitor.
de Bruijne J, van de Wetering de Rooij J, van Vliet AA, Zhou XJ, Temam MF, Molles J, Chen J, Pietropaolo K, Sullivan-Bólyai JZ, Mayers D, Reesink HW. de Bruijne J, et al. Among authors: sullivan bolyai jz. Antimicrob Agents Chemother. 2012 Aug;56(8):4525-8. doi: 10.1128/AAC.00451-12. Epub 2012 Jun 4. Antimicrob Agents Chemother. 2012. PMID: 22664976 Free PMC article. Clinical Trial.
A cocktail of human monoclonal antibodies broadly neutralizes North American rabies virus variants as a promising candidate for rabies post-exposure prophylaxis.
Ejemel M, Smith TG, Greenberg L, Carson WC, Lowe D, Yang Y, Jackson FR, Morgan CN, Martin BE, Kling C, Hutson CL, Gallardo-Romero N, Ellison JA, Moore S, Buzby A, Sullivan-Bolyai J, Klempner M, Wang Y. Ejemel M, et al. Among authors: sullivan bolyai j. Sci Rep. 2022 Jun 7;12(1):9403. doi: 10.1038/s41598-022-13527-0. Sci Rep. 2022. PMID: 35672343 Free PMC article.
Blocking Borrelia burgdorferi transmission from infected ticks to nonhuman primates with a human monoclonal antibody.
Schiller ZA, Rudolph MJ, Toomey JR, Ejemel M, LaRochelle A, Davis SA, Lambert HS, Kern A, Tardo AC, Souders CA, Peterson E, Cannon RD, Ganesa C, Fazio F, Mantis NJ, Cavacini LA, Sullivan-Bolyai J, Hu LT, Embers ME, Klempner MS, Wang Y. Schiller ZA, et al. Among authors: sullivan bolyai j. J Clin Invest. 2021 Jun 1;131(11):e144843. doi: 10.1172/JCI144843. J Clin Invest. 2021. PMID: 33914704 Free PMC article.
33 results